Doximity company profile
Company profile
Doximity has 880 employees and is headquartered in San Francisco, United States.
Known to doctors as the Doximity platform, the company runs a professional network where medical staff follow clinical research, video summaries and peer updates in a personalized feed, and where drug makers and health systems also place sponsored content. Its newer tools include Ask, an AI assistant for finding evidence-based answers during patient care, Scribe, an AI tool that drafts clinical notes, and AMiON for on-call scheduling. Its clients range from nurse practitioners and medical students to pharmaceutical manufacturers and hospital networks, and its activity is focused on the United States.
In the fiscal year ended March 2026, revenue rose 13.1% to $644.9 million and net income reached $196.1 million. Incorporated in 2010 as 3MD Communications, the company took the Doximity name that June. It is headquartered in San Francisco and has 880 employees.
Company facts
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Headquarters
- 500 3rd Street, 94107, San Francisco
- Employees
- 880
- Chief executive
- Jeffrey Tangney
- Founded
- 2010
- Fiscal year
- April - March
- Listing
- DOCS · NASDAQ
- Currency
- USD
- ISIN
- US26622P1075
- Website
- doximity.com
Doximity and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| DoximityDOCS | United States | $5.13B | 880 | 27.1% | 39.9 |
| Tempus AITEM | United States | $9.86B | 3,800 | -18.5% | — |
| Veeva SystemsVEEV | United States | $43.1B | 7,928 | 29.9% | 43.6 |
| M32413 | Japan | $7.04B | 17,010 | 19.5% | 24.4 |
| XtalPi Holdings2228 | Hong Kong SAR China | $3B | 1,623 | -124.6% | — |
| Pro MedicusPME | Australia | $13.08B | 153 | 74.9% | 76.0 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
